NEW YORK (GenomeWeb) – Molecular diagnostics developer Exact Sciences announced today that it plans to offer 8.5 million shares of common stock for sale at $15.50 a share.

The company — which earlier this week said it would offer 7 million shares but raised the amount of the offering because of market demand — said it will use the proceeds for general corporate and working capital purposes, to fund the development of new products, and to fund the commercialization of its Cologuard colorectal cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.